Equities

Redsense Medical AB (publ)

Redsense Medical AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)6.70
  • Today's Change-0.14 / -2.05%
  • Shares traded3.05k
  • 1 Year change-24.72%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Redsense Medical AB (publ) is a Sweden-based company, which is primarily involved in the healthcare industry. The Company is active within the field of hemodialysis. It operates as a manufacturer of blood loss detection device that is designed to alarm on blood leakage from the venous blood access. The Company's Redsense system consists of an alarm unit, an extension fiber and a non invasive sensor patch. When the sensor patch is placed over the blood access, it detects any blood coming in contact with the sensor. This can occur if the needle is accidentally dislodged or if blood is leaking during dialysis. The Redsense system is designed to alarm when blood reaches the sensor, so the dialysis caregiver or observing person at home, can apply appropriate action when a venous needle dislodges.

  • Revenue in SEK (TTM)23.77m
  • Net income in SEK-3.98m
  • Incorporated2003
  • Employees5.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dignitana AB86.49m-25.27m86.99m29.00--8.89--1.01-0.3268-0.32681.130.12151.742.7615.193,203,482.00-50.91-42.21-122.38-68.9169.5666.09-29.22-57.290.5202-9.970.609--17.9020.5922.52---15.31--
Glycorex Transplantation AB (publ)31.03m-27.83m87.53m15.00--2.39--2.82-0.3768-0.37680.42010.51860.4120.83823.691,348,913.00-36.96-11.30-46.32-13.1782.9191.60-89.70-33.241.09-71.860.2084---17.04-2.15-254.06---0.5593--
SciBase Holding AB (publ)25.71m-59.24m92.65m27.00--1.75--3.60-0.4495-0.44950.18840.24090.2990.73284.04952,222.30-68.89-68.63-89.67-87.7770.0261.28-230.41-300.203.11-62.080.00--29.9327.50-28.75--5.15--
ScandiDos AB61.35m-9.67m94.64m26.00--2.17--1.54-0.2068-0.20681.260.7660.81841.316.881,978,871.00-12.90-12.60-23.54-21.7650.3951.58-15.76-15.370.9476-6.360.00---1.824.36-60.62---19.29--
Kontigo Care AB29.65m1.75m94.86m10.0042.661.9517.893.200.06940.06941.111.510.6241--8.03--3.68-0.42145.03-0.619569.9366.315.89-0.5205--10.000.0569--1.8016.95-92.68--44.94--
Observe Medical ASA-98.44bn-98.44bn95.57m5.00--0.6194----------0.5635-----------32.60---49.80--32.83---256.250.193--0.3425--43.14204.81-18.82--32.69--
Luxbright AB4.20m-22.23m105.36m10.00--3.54--25.07-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Immunovia AB (publ)885.00k-116.12m106.92m10.00--2.91--120.81-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Episurf Medical AB12.80m-79.70m107.16m26.00--1.06--8.37-0.2072-0.20720.03010.15580.1059--5.57457,142.80-66.09-47.46-75.45-52.01-----624.22-1,019.296.17--0.0296--53.6219.78-22.64---0.4158--
Vo2 Cap Holding AB (publ)348.03m-55.15m108.36m94.00--0.6021--0.3114-0.9759-0.97596.463.160.7992--8.213,378,952.00-12.66-0.2564-17.29-0.383935.7823.36-15.84-0.2409---6.950.1429---26.0985.65-57.92---17.96--
Phase Holographic Imaging PHI AB9.12m-21.81m109.02m14.00------11.95-0.8695-0.86950.3634-0.02730.23730.65981.18651,571.40-56.73-62.04-88.25-79.1671.0663.16-239.04-328.500.1916-5.611.04--6.1617.9612.98--22.76--
Iconovo AB2.92m-40.21m109.52m28.00--0.7354--37.55-2.74-2.740.1967.020.0215--1.14100,561.70-29.61-25.43-33.16-28.24635.97134.57-1,378.66-215.16---1,179.070.0668---58.65-9.884.71--34.70--
Redsense Medical AB (publ)23.77m-3.98m112.48m5.00--3.50--4.73-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
BibbInstruments AB0.00-11.84m114.18m4.00--3.31-----0.4417-0.44170.001.180.00-------31.46-39.57-33.52-42.71--59.36---8,032.404.34--0.00------2.72---1.94--
SpectraCure AB (publ)2.36m-21.18m136.18m13.00--1.16--57.61-0.218-0.2180.02431.210.0166--24.63157,600.00-14.82-12.75-15.91-13.62442.39195.30-895.85-494.40----0.0494---3.30--19.46------
Toleranzia AB0.00-7.12m137.11m11.00--0.6724-----0.0361-0.03610.000.75260.00----0.00-4.31-7.45-4.56-7.78------------0.0481------11.79--63.90--
Data as of Nov 13 2024. Currency figures normalised to Redsense Medical AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Swedbank Robur Fonder ABas of 30 Sep 2024519.77k0.00%
Aktia Bank Plc (Investment Management)as of 30 Sep 2024310.00k0.00%
Schroder Investment Management Ltd.as of 31 Dec 2023141.14k0.00%
Evli Fund Management Co. Ltd.as of 30 Aug 20241.00k0.00%
Discover Capital GmbHas of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.